Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Quarterly Earnings Results, Misses Estimates By $0.47 EPS

03 Aug 2026, 20:58 by Amy Steele · The Cerbat Gem

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) issued its earnings results on Monday. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47), FiscalAI reports. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period last year, the business posted ($8.25) EPS.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

Record revenue of $1.21 billion rose 16% year over year, prompting Jazz to raise 2026 revenue guidance to $4.60 billion–$4.75 billion. Adjusted EPS was $5.71, while first-half operating cash flow reached $824 million.
XYWAV sales increased 13% to $471 million, with approximately 525 net patient additions and limited uptake of high-sodium generics. Jazz now expects double-digit XYWAV growth in 2026 and raised rare-sleep revenue guidance to $2.025 billion–$2.125 billion.
Epidiolex sales grew 16% to $292 million on strong underlying demand, particularly among adult and long-term-care patients. Jazz is pursuing a capsule formulation and several clinical trials to expand usage across additional treatment-resistant seizure populations.
Jazz expressed high confidence in zanidatamab’s approval for first-line HER2-positive metastatic GEA by the August 25 PDUFA date and said it is prepared for launch. The company highlighted median overall survival of 26.4 months in the combination arm and expects additional doublet overall-survival data in the third quarter.
Zepzelca sales rose 42% to $106 million, driven by first-line maintenance adoption, but Jazz plans to submit a labeling supplement removing the second-line indication after the LAGOON results. Management expects the historical second-line business to continue eroding, with a possible acceleration following the label change.

Jazz Pharmaceuticals Stock Down 0.5%

NASDAQ JAZZ traded down $1.28 on Monday, reaching $251.58. The company had a trading volume of 1,493,225 shares, compared to its average volume of 698,212. The company’s fifty day moving average is $239.50 and its 200-day moving average is $207.30. The firm has a market capitalization of $15.80 billion, a price-to-earnings ratio of 27.67, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. Jazz Pharmaceuticals has a 1-year low of $105.00 and a 1-year high of $261.30.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This represents a 2.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Heather Ann Mcsharry sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 13,098 shares of company stock valued at $3,131,906. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP bought a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $127,344,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Jazz Pharmaceuticals by 258.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock worth $93,160,000 after acquiring an additional 395,000 shares during the period. Schonfeld Strategic Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 592.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock worth $57,523,000 after acquiring an additional 373,383 shares during the period. AQR Capital Management LLC raised its stake in Jazz Pharmaceuticals by 62.1% in the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after acquiring an additional 304,463 shares during the period. Finally, Woodline Partners LP lifted its holdings in Jazz Pharmaceuticals by 710.7% during the 3rd quarter. Woodline Partners LP now owns 264,968 shares of the specialty pharmaceutical company’s stock valued at $34,923,000 after purchasing an additional 232,284 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JAZZ. Bank of America raised their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Truist Financial cut their target price on shares of Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company lifted their target price on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $259.06.

View Our Latest Stock Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.